Cancer Trials Ireland sites across Ireland continue to build momentum in the international EORTC-sponsored DE-ESCALATE study, with eight out of ten participating Irish sites now activated and open to enrolment.
The study, sponsored by the European Organisation for Research and Treatment of Cancer (EORTC), is being delivered in Ireland through Cancer Trials Ireland’s national network of participating sites, investigators, research nurses and trial teams.
Recruitment activity in Ireland has continued to grow steadily in recent months, with Tallaght University Hospital leading enrolment efforts following activation in December 2025 and nine patients recruited to date.
Additional participating sites including Cork University Hospital, St James’s Hospital, and University Hospital Limerick have also achieved first patient enrolment, while University Hospital Galway, Beaumont Hospital, Mater Misericordiae University Hospital and Beacon Hospital are now activated and progressing recruitment activity.
Overall accrual in Ireland has now reached 12 patients.
The progress reflects significant collaboration across participating sites and continued engagement from investigators and research teams supporting delivery of the study in Ireland. Early pre-screening activity and coordinated site set-up efforts have helped accelerate activation and recruitment timelines across the network.
The DE-ESCALATE study forms part of wider international efforts coordinated by EORTC, with Ireland contributing through Cancer Trials Ireland’s national clinical trials infrastructure and participating hospital sites.
With most Irish sites now activated, the focus will continue on supporting recruitment and maintaining momentum across the network throughout 2026.